See link for details: https://lnkd.in/eQ7Mm4pU
Savara Inc.
Pharmaceutical Manufacturing
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
About us
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com
- Website
-
http://www.savarapharma.com
External link for Savara Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- United States
- Type
- Public Company
- Founded
- 2007
- Specialties
- biotech, biopharma, pulmonary, dry-powder, dpi, therapeutics, lung, respiratory, aerosol, inhaler, drug delivery, and rare disease
Locations
-
Primary
United States
United States, US
Employees at Savara Inc.
Updates
-
See link for details: https://lnkd.in/eNDEiAXQ
-
See link for details: https://lnkd.in/eZ9ccNXD
-
See link for details: https://lnkd.in/e7qkZH9k
-
See link for details: https://lnkd.in/eFWqYtws
-
See link for details: https://lnkd.in/eqtr6XHj
-
See link for details: https://lnkd.in/eha7iQE4
-
Savara is proud to recognize #RareDiseaseDay, a globally-coordinated movement working towards raising awareness and generating change for the 300 million people worldwide living with a rare disease, their families and carers. At Savara, we are focused on improving the lives of people with autoimmune pulmonary alveolar proteinosis (aPAP), a serious and rare lung disease with no approved pharmacological treatment options. #raredisease #shareyourcolours PAP Foundation, Inc.
-
See link for details: https://lnkd.in/gyK7ft3T